Inconsistent information about drug-drug interactions can cause variations in prescribing, and possibly increase the incidence of morbidity and mortality. Th e aim of this study was to assess whether there is an inconsistency in drug-drug interaction listing and ranking in three authoritative, freely accessible online drug information sources: Th e British National Formulary; Th e Compendium about Drugs Licensed for Use in the United Kingdom (the Electronic Medicines Compendium) and the Compendium about Drugs Licensed for Use in the United States (the DailyMed). Information on drug-drug interactions for thirty drugs which have a high or medium potential for interactions have been selected for analysis. In total,  drug-drug interactions were listed in all three drug information sources, of these  were ranked as the interactions with the potential of clinical signifi cance. Comparative analysis identifi ed that . of interactions were listed in only one drug information source, and . of interactions were ranked in only one drug information source. Only . listed and . ranked interactions were identifi ed in all three information sources. Intraclass correlation coeffi cient indicated a weak correlation among the three drug information sources in listing (.), as well as in ranking drug interactions (.). Th is study showed inconsistency of information on drug-drug interaction for the selected drugs in three authoritative, freely accessible online drug information sources. Th e application of a uniform methodology in assessment of information, and then the presentation of information in a standardized format is required to prevent and adequately manage drug-drug interactions.
INTRODUCTION
Drug-drug interactions are the important cause of therapeutic problems and increased number of hospital admissions within the European Union [] . The study which investigated the causes of hospital admissions of  patients in the United Kingdom (UK) showed that drugdrug interactions were responsible for about  of hospital admissions because adverse drug effects [] . The withdrawal half of drugs from the market in the United States (US), because of safety reasons, during the period -, was associated with important drug interactions [] . The adverse effects of drugs which is a consequence of drug interactions, can be prevented by taking appropriate action. It was estimated that more than threequarters of clinically significant drug interactions can be avoided [] . For adequate management of drugdrug interactions, the access to relevant information sources is very important for health professionals [] . There are numerous compendia with information on the drug interactions. However, compendia often do not document methodology for listing as well as ranking the potential clinical severity of drug-drug interactions. Th is may be reason for inconsistent informing. Inconsistent drug-drug interaction information can cause variations and confusions in prescribing, possibly increasing the incidence of morbidity and mortality [] . As an example, according to the British National Formulary (the BNF) and the Summary of Product Characteristics (SmPC) of amiodarone licensed for use in the UK coadministration of amiodarone and beta-blockers should be avoided, but can be safely administered under close monitoring according to other authoritative sources [, ] . Stockley's Drug Interactions even reports that coadministration may be therapeutically benefi cial. Additionally, previous studies have shown that there is inconsistency in drug-drug interaction information [, -] . Studies were included standard drug compendia such as the BNF, the Vidal, the Micromedex® (Drug-Reax) program, the Drug Interactions Facts, the US Pharmacopeia Drug Information, the American Hospital Formulary Service Drug Information (AHFS), Stockley's Drug Interactions, Hansten's Drug Interactions Analysis and Management, German Summary of Product Characteristics (SmPCs), in printed or electronical form. When it comes to information sources which doctors and pharmacists use to identify potential drug-drug interaction, the results of previous studies have shown that electronic references have been consulted most often (MicroMedex, Internet, PDA, UpToDate)  and , subsequently. Printed information sources (AHFS, Facts & Comparasions) have been used by  of doctors and  of pharmacists [] . Health professionals often do not have specialized interaction textbooks to hand or support drug-drug interactions screening programs [] . Th erefore, the aim of this study is to identify whether there is consistency in listing as well as ranking clinical signifi cance of drug-drug interaction in three authoritative, freely accessible online drug information sources.
MATERIALS AND METHODS

Criterion for the selection of information sources for analysis
Th ree analysed compendia were the BNF [] ; the Compendium about Drugs Licensed for use in the UK (the electronic Medicines Compendia (eMC)) [] and the Compendium about Drugs Licensed for Use in the USA (the DailyMed) [] . Th e BNF is a publication of the Medical Society of the United Kingdom and the Royal Pharmaceutical Society of Great Britain, it is independent, reliable and practice-oriented source of information which is widely used by clinicians around the world [] . Th e eMC and the DailyMed contain information about drugs in the form of SmPC. Th e SmPC represents the legal basis of information for health professionals on how to use the medical product safely and effectively [, ] . These three selected compendia are characterized by the unlimited access to information by the Internet.
Criteria for selection of drugs for analysis and comparison of information
Drugs selected for analisys have a high potential for interactions (for example fluconazole) or belong to major therapeutic classes of drugs which are most frequently involved in drug interactions (for example hydrochlorothiazide) (Table ) [, ] . No more than one drug of a given therapeutic class (third level according to Anatomical Th erapeutic Chemical Classifi cation System) was included in analysis because many drug interactions may be common to members of the same class. SmPC for oral route of administration was randomly chosen in conditions where the drug was licensed for use under different brand names. In the BNF the section "Appendix -Drug Interactions" was consulted, in the other two compendia the section "Interactions with other medical product and other forms of interaction" was always evaluated first and in case of cross-references, information included in the sections "Dosage and method of administration", "Contraindications" and "Special warnings and precautions for use" were also taken into account. All drug-drug interactions for  selected drugs were identifi ed in all three compendia. Comparison of drug-drug interaction information was made on the basis of two criteria: . Whether drug-drug interaction was listed in the selected source of information at all. . Are there clear recommendations for management of drugdrug interaction (for example, adjustment of dosing regimen), that is, whether the drug-drug interaction was considered clinically signifi cant. The BNF uses bolding to mark clinically significant interactions, which are assessed as potentially risky. Thus, it is recommended that drug co-administration is avoided or carefully monitored. In the other two compendia, clinically significant interactions were considered those where according to SmPC there are contraindications for a combined administration of the drugs, or SmPC suggests avoiding the combined administration of the drugs or using drug with modifi cation therapeutic regimen and/or closer monitoring of the patient because of clinical signifi cance of drug-drug interaction. Additionally, if a case that SmPC did not comment on the signifi cance of interactions, we considered as clinically significant pharmacodynamic (PD) interactions which may have a signifi cant risk for the patient and require intervention [, ] and pharmacokinetic (PK) interactions which increase and decrease PK parameters (area under the curve, elimination half-life or total clearance), at least  and , respectively and for the compounds with a narrow therapeutic window at least  and , respectively [] . 
Statistical analysis
The consistency in listing and in ranking of clinically significant drug interactions among three compendia was estimated using descriptive statistics and calculating intraclass coefficient of correlation (ICC) [] .
RESULTS
Listed drug-drug interactions
Overall,  interactions were listed for  analyzed drugs in all three compendia (range - per drug).
The most comprehensive source of information is the BNF with  listed drug-drug interactions which is almost twice as more than in the DailyMed (Table ) . Table  also shows how interactions were listed in each individual compendium reflecting their consistency. Thus, the majority of drug-drug interactions  (.) were listed in only one compendium (Table ) , while was in all three compendia  (.) drug interactions were listed. The intraclass correlation coefficient (ICC) with calculated value of . indicates a weak correlation among the three compendia in listed drug-drug interactions (values < . indicate a weak correlation) [] .
Ranked drug-drug interactions
Overall,  interactions were ranked as clinically significant in all three compendia (range - per drugs). The number of interactions per compendium is in the range from  in the DailyMed to  in the BNF ( Table ) . The proportion of ranked interactions in relation to the total number of listed drug-drug interactions is the greatest in the DailyMed -.. [] . Comparative analysis showed that between . and . of interactions were listed in only one of the compendia, while between . and . of interactions were listed in all fi ve compendia, depending on analyzed therapeutic class. When it comes to ranking the clinical signifi cance of the interaction, there were not any ranked interactions which were identifi ed in all fi ve compendia for four therapeutic classes (benzodiazepines, beta blockers, calcium channel blockers, NSAIDs), whereas in the class of ACE inhibitors, . of ranked interactions were identifi ed in all fi ve compendia. Bergk et al. [] compared information about clinically significant interactions (listing, class labeling, description of effects, recommendations for management) in the German SmPC and three standard drug interactions sources, the DRUGDEX, Hansten/Horn's Drug Interactions Analysis and Management and Stockley's Drug Interactions. Th e results showed that information was equivalent for only . (/) of analyzed interactions, . of interactions were not identified in German SmPC and  of information was not sufficiently informative. Th e Vitry's study analyzed  drugs which have a high potential for interactions or belong to major therapeutic classes of drugs which are most frequently involved in drug interactions. Only . of major drug interactions were listed in all four analyzed international compendia, i.e. the BNF, the Vidal (French drug compendium) and two US compendia, the Drug Interaction Facts and the Micromedex® program while between  and  interactions which were classifi ed as major were listed in only one of the compendia [] . Reggi et al compared the consistency of information on indications, dosage in adult population, side eff ects and precautions for ciprofl oxacin, fl uoxetin and nifedipine in the BNF, the UK SmPC and the US SmPC. Th eir results showed high consistency of information in the BNF (as a golden standard) and information in the UK SmPC for all three analyzed drugs, and high consistency of information in the BNF and information in the US SmPC for two analyzed drugs (degree of information agreement was ≥  for grouped all varibles) [] . In contrast, according to results of our study, these compendia were not consistent for information referring to drug-drug interactions. It means if we observe three information sources (the BNF, the UK SmPC and the US SmPC), the consistency of drug information depends on the observed variables. Thus, information for variables indications, dosing in adult population, side effects and precautions are consistent, while information for drug-drug interactions are not consistent. Th erefore, fi ndings suggest that there is only need to improve information agreement among the BNF, the UK SmPC and the US SmPC for variable drug-drug interactions. However, using different approaches in evaluation of drug information in Reggi's et al and our study requires further researches for fi nal conclusion. There are several limitations for this study. Firstly, we did not analyze all the interactions of all drugs. Also, drugs which belong to the same therapeutic class were not selected for analysis. However, previously published studies indicate that it is unlikely that the selection of drugs for the analysis contributed to the inconsistency of information on drug-drug interactions [, , ] . Secondly, the selection of the SmPC for analysis may affect research results. International comparative study showed that drug information contained in the SmPCs different brand names of a same compound can be different even within one country [] . Finally, information in compendia in which there were not clear recommendations for the management of interactions may result in a diff erent interpretation of clinical signifi cance of the interaction. For example, prolonged regular use of paracetamol may enhance anticoagulant eff ects of warfarin and other coumarins [, ] . Or, co-administration of hydrochlorthiazide and iodine-based contrast agents in high doses may result in increased risk of acute renal failure [] . Terms prolonged regular use of paracetamol and use of iodine-based contrast agents in high doses are not precisely defi ned. To achieve uniformity in ranking a clinical signifi cance of interactions, Hansten et al.
[] besides quality of evidence and severity of side-eff ects, were proposed and additional criteria for classifi cation of drug-drug interactions, those were consistency of the reported eff ect with the known interactive properties of two drugs, frequency in using two drugs in general patient population and its relationship with the number of reported cases of adverse drug interaction, and medico-legal consideration (i.e. if there are warnings in drug labeling). Also, Partnership to prevent drug-drug interactions developed sixteen criteria to defi ne a list of clinically important drugdrug interactions in community and ambulatory pharmacy settings. Criteria (i.e. questions) were grouped in four sections: evidence supporting the interaction, severity of the interaction, probability of the interaction, and probability of coadministration of the interacting drugs. Th e answer to every question was ranged from  to , and fi nally,  clinically important drug-drug interactions were identifi ed by consensus process [] . However, these initiatives to improve classifi cation of drug interactions have not contributed to consistency in listing and ranking drug interactions in information sources.
CONCLUSION
The study has shown the inconsistency of information on drug interactions in three authoritative, freely accessible online compendia in listing and in ranking of clinical significance of drug-drug interactions. Th e inconsistency enhances for both study criteria with increasing number of drug information sources. Th e results are more signifi cant because analyzed drugs belong to the class of drugs with high or frequent potential for clinically signifi cant interactions. Since these analyzed compendia do not document methodology in listing as well as in ranking of the potential for clinical significance interactions, the application of a uniform methodology in assessment of information based on the best evidence, and then the presentation of information in a standardized format is required to prevent and adequate management of adverse eff ects which are the consequence of drug-drug interactions.
